
SSG 2025: Asa Waldstein on FDA, FTC and NAD enforcement trends
Apex Compliance’s Asa Waldstein shares valuable insights for those seeking to avoid an FDA warning letter, a competitor case with the NAD or a referral to the FTC due to ad claims non-compliance.













































